Royal Bank of Canada lowered shares of IGM Biosciences (NASDAQ:IGMS – Free Report) from an outperform rating to a sector ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

IGM Biosciences (NASDAQ:IGMS – Get Free Report) had its target price reduced by research analysts at Truist Financial from ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

Fintel reports that on January 10, 2025, Stifel downgraded their outlook for IGM Biosciences (NasdaqGS:IGMS) from Buy to Hold ...

IGM Biosciences (IGMS) stock faces sharp selloff as the company abandons two therapeutic candidates, triggering Wall Street ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...

RBC Capital analyst Brian Abrahams downgraded IGM Biosciences (IGMS) to Sector Perform from Outperform with a price target of $1.50, down from ...

IGM Biosciences shares dived 69% in premarket trading a day after the company said it would halt development of two of its treatments. Shares were trading around $1.94. The stock is up 1.5% on the ...